Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ascendis Pharma (ASND – Research Report), CareDx (CDNA – Research Report) and Ligand Pharma (LGND – Research Report).
Ascendis Pharma (ASND)
Oppenheimer analyst Leland Gershell maintained a Hold rating on Ascendis Pharma today. The company’s shares closed last Thursday at $93.77.
According to TipRanks.com, Gershell has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ascendis Pharma with a $141.50 average price target, which is a 46.8% upside from current levels. In a report issued on November 7, TD Cowen also maintained a Hold rating on the stock with a $110.00 price target.
See the top stocks recommended by analysts >>
CareDx (CDNA)
In a report released today, Alexander Nowak from Craig-Hallum maintained a Hold rating on CareDx, with a price target of $9.00. The company’s shares closed last Thursday at $7.48.
According to TipRanks.com, Nowak is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on CareDx is a Moderate Buy with an average price target of $10.33, implying a 29.1% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Hold rating on the stock.
Ligand Pharma (LGND)
In a report released today, Matt Hewitt from Craig-Hallum reiterated a Buy rating on Ligand Pharma, with a price target of $135.00. The company’s shares closed last Thursday at $54.49, close to its 52-week low of $49.24.
According to TipRanks.com, Hewitt is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Ligand Pharma is a Strong Buy with an average price target of $121.00, a 120.0% upside from current levels. In a report issued on November 1, H.C. Wainwright also reiterated a Buy rating on the stock with a $144.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ASND:
- Ascendis Pharma Reports Third Quarter 2023 Financial Results
- ASND Earnings this Week: How Will it Perform?
- Ascendis Pharma Announces Timing of Third Quarter 2023 Financial Results and TransCon PTH NDA Resubmission
- Ascendis Pharma to resubmit NDA for TransCon PTH before mid-November
- Ascendis Pharma presents updated, new TransCon IL-2 data
